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myelin-related disorders such as multiple sclerosis and leukodystrophies, for which restoration of oligodendrocyte function would be an effective treatment, are poised to benefit greatly from stem cell biology. Progress in myelin repair has been constrained by difficulties in generating pure populations of oligodendrocyte progenitor cells (oPcs) in sufficient quantities. Pluripotent stem cells theoretically provide an unlimited source of oPcs, but current differentiation strategies are poorly reproducible and generate heterogenous populations of cells. here we provide a platform for the directed differentiation of pluripotent mouse epiblast stem cells (episcs) through defined developmental transitions into a pure population of highly expandable oPcs in 10 d. these oPcs robustly differentiate into myelinating oligodendrocytes in vitro and in vivo. our results demonstrate that mouse pluripotent stem cells provide a pure population of myelinogenic oligodendrocytes and offer a tractable platform for defining the molecular regulation of oligodendrocyte development and drug screening.
Myelin is an essential component of the vertebrate nervous system and serves as an electrical insulator for the effective conduction of action potentials along nerve axons. The incapacitating effects of myelin defects impact millions of people worldwide and are readily apparent in acquired demyelinating conditions such as multiple sclerosis and cerebral palsy as well as congenital dysmyelinating disorders such as Pelizaeus-Merzbacher disease and vanishing white matter disease. Curative therapies currently remain unfeasible owing to the inability to promote remyelination in response to myelin loss. Remyelination would necessitate either the pharmacologic restoration of the myelinating capacity of endogenous cells or transplantation of exogenous, functional oligodendrocyte progenitor cells (OPCs) 1 . OPCs are an important cell type in the central nervous system for myelin maintenance and repair as they are uniquely capable of responding to extrinsic cues and generating myelinogenic cells 2 . Notably, even mature oligodendrocytes do not appear to maintain an intrinsic ability to rapid and robust generation of functional oligodendrocyte progenitor cells from epiblast stem cells respond to new myelination cues, and therefore bona fide OPCs are a sought-after target for myelin-repair strategies.
Previous studies have created excitement for myelin repair by demonstrating that oligodendrocytes may be derived from neural stem cells and pluripotent stem cells. These approaches, however, have yet to closely match the pace of normal development or yield a high percentage of oligodendrocytes. Current strategies often generate a mixture of uncharacterized, tripotent neural precursors, not OPCs, and rely heavily on immunopanning, antibiotic resistance or cell-sorting techniques to improve population characteristics [3] [4] [5] [6] . Thus far the field has been lacking a controlled and scalable production of pure, committed OPCs.
Our study aimed to establish precise methodologies to control the production of pure, functional mouse OPCs. We show that mouse pluripotent stem cells can be guided through defined developmental transitions to rapidly produce a pure population of expandable mouse OPCs. These pluripotent stem cell-derived OPCs function to generate myelinogenic oligodendrocytes and serve as a tractable platform for the identification of small molecules that promote myelination. Future translation of our results to human pluripotent stem cells offers promise for cell-based strategies for myelin repair.
results

region-specific neuroepithelium from episcs in 5 d
The allocation of pluripotent cells in the embryo to their somatic and germ cell fates is orchestrated by a complex array of signals emanating from distinct regions 7 . We postulated that precise control of these signals would allow for the routine and specific generation of sufficient quantities of OPCs from pluripotent stem cells ( Supplementary Fig. 1 ). Our studies focused on mouse epiblast stem cells (EpiSCs) owing to their in vitro tractability and because they have defining features and a developmental state in common with human embryonic stem cells and human induced pluripotent stem cells (iPSCs). We have previously shown that EpiSCs are an ideal system to define the molecular regulation of cell-fate transitions during early development 8 . EpiSCs are isolated from either pre-or early post-implantation mouse embryos and represent the most proximal cell type to all the somatic and germ cell lineages in the developing embryo [8] [9] [10] .
To specify EpiSCs into the neuroectodermal lineage, we modulated both the activin-nodal and bone morphogenetic protein (BMP) signaling pathways with small-molecule inhibitors (Online Methods). Previous work in frog, mouse and pluripotent stem cells has demonstrated that TGF-β family signaling, through intracellular SMAD effectors, has an important role in neural induction 8, [11] [12] [13] . Using these developmental cues, we treated EpiSCs with SB431542, an inhibitor of Alk4, Alk5 and Alk7 (activin-nodal signaling), dorsomorphin or LDN-193189, inhibitors of Alk2, Alk3 and Alk6 (BMP signaling), and noggin, a BMP antagonist. In response, the EpiSCs rapidly downregulated the expression of pluripotency genes such as Pou5f1 (also known as Oct3/4), upregulated neuroectodermal genes such as Pax6 and Sox1, and underwent morphological changes to form radially organized neural rosettes ( Fig. 1 and Supplementary Fig. 2 ). This differentiation strategy was extremely robust and resulted in >99% of EpiSC colonies forming rosettes expressing both Pax6 and Sox1 (Pax6 + and Sox1 + ) ( Supplementary Fig. 2c ).
Our next step was to pattern the 'naive' EpiSC-derived neural rosettes in a region-specific manner. In the developing neural tube, specific cellular precursor domains are established by local signals from the surrounding tissues 14 . In the developing spinal cord OPCs first emerge from the ventral ventricular zone of the neural tube in response to sonic hedgehog (SHH) and other signals from the notochord and floor plate [15] [16] [17] . Therefore, we treated our day-4 EpiSC-derived neural rosettes for 1 d with specific concentrations of retinoic acid and SHH in the continued presence of noggin to pattern them in a region-specific way (Online Methods) 18 . This treatment resulted in the upregulation of OPC-relevant transcription factors Olig2 and Nkx2.2 (Fig. 1e) . The expression pattern of these factors in the rosettes mimicked the non-overlapping expression in the ventral ventricular zone of the developing mouse neural tube 18, 19 (Fig. 1f) . Additionally, EpiSC-derived patterned rosettes expressed proper posterior-related Hox genes, thus confirming their spinal cord identity along the rostrocaudal axis 20 (Supplementary Fig. 3 ). These results demonstrate that the provision of guiding developmental cues leads to the proper specification and patterning of pluripotent cells into region-specific cells of the developing spinal cord in 5 d.
expandable oPcs from patterned neuroectoderm
We next determined whether we could differentiate the patterned EpiSC-derived neural rosettes into a continuously dividing OPC population. After their specification in vivo, OPCs proliferate in response to platelet-derived growth factor (PDGF) and fibroblast growth factor (FGF) signals 21, 22 and migrate extensively to populate the central nervous system. To recapitulate these events, we dissociated our patterned EpiSC-derived neural rosettes and plated them onto a laminin substrate (we denoted this primary passaging event 'passage 0') in the presence of PDGF-AA, FGF2 and SHH. Upon passage, our EpiSC-derived neural rosettes immediately gave rise to both βIII-tubulin + neurons and presumptive OPCs that expressed Olig2 or Nkx2.2 ( Supplementary  Fig. 4a,b) . These results recapitulate in vivo cell-specification events at the ventral ventricular zone of the developing spinal cord that are known to give rise to both neurons and OPCs 23 . In our cultures the neurons did not persist beyond the first 3 d of culture ( Supplementary Fig. 4c ). However, the presumptive OPCs developed strong, co-expression of Olig2 and Nkx2.2 and rapidly proliferated in the presence of FGF2, PDGF and SHH to produce a confluent and nearly homogeneous population of cells in 5 d (10 d from initial differentiation of the EpiSCs) ( Fig. 2a-c and Supplementary Fig. 4d-f) . These EpiSC-derived OPCs exhibited a typical bipolar morphology and expressed transcription factors and cell surface markers such as Olig1, Olig2, Nkx2.2, Sox10, PDGFRα, A2B5 and NG2 (Cspg4) consistent with their in vivo counterparts 24 (Fig. 2) . The EpiSC-derived OPCs were synchronous and highly pure as ~90% co-expressed the OPC surface markers NG2 and PDGFRα, as determined by flow cytometry without selection or sorting ( Fig. 2e) . Additionally, we could expand these EpiSC-derived OPCs for at least eight passages, yielding previously unobtainable numbers (>10 12 cells) of pure OPCs (Fig. 2d) . To demonstrate the robustness of our protocol we simultaneously differentiated four independently derived EpiSC lines (including lines from mice of different genders, strains and developmental stage). All four cell lines differentiated efficiently into OPCs without any cell line-specific modifications to the protocol (Supplementary Fig. 5 ). These results demonstrate that highly expandable, defined populations of OPCs can be rapidly and robustly generated from pluripotent stem cells.
oPc differentiation and functional myelination
To determine the differentiation capacity of our EpiSC-derived OPCs, we treated them with thyroid hormone (T3), which is known to be important both in vitro and in vivo in regulating the transition of OPCs into oligodendrocytes, in the absence of both FGF2 and PDGF-AA 25 . These conditions caused the EpiSCderived OPCs to stop proliferating and differentiate exclusively into oligodendrocytes over a 2-4-d time course (Fig. 3a-c and Supplementary Video 1). Undifferentiated OPCs did not express the oligodendrocyte cell-surface marker O4, but by day 2 of differentiation greater than 64% of the cells were strongly O4 + with a multiprocessed morphology, and the rest remained Olig2 + OPCs (cells manually counted from random fields of independent lines, n > 480 cells). By day 3, these O4 + oligodendrocytes had upregulated the classical and defining markers of bona fide oligodendrocytes such as myelin basic protein (Mbp), proteolipid protein 1 (Plp1), myelin-associated glycoprotein (Mag) and myelin oligodendrocyte glycoprotein (Mog) 24 (Fig. 3b,c) . The differentiation was highly specific as we never observed GFAP + astrocytes or βIII-tubulin + neurons. By day 4, the overwhelming majority of EpiSC-derived OPCs had become oligodendrocytes, but cell death and rare proliferation events make exact quantification challenging without large-scale time-lapse lineage analysis. To test the robustness of our protocol, we differentiated OPCs derived from four independent EpiSC lines into oligodendrocytes and noted no apparent differences in the efficiency or timing of differentiation ( Supplementary Fig. 5 ). Freezing-thawing and extensive expansion of the OPCs also did not alter their properties or ability to differentiate as all passages tested had highly correlated global gene expression patterns and generated oligodendrocytes with similar timing and efficiency ( Supplementary Fig. 6a-d) .
To examine the functional properties of EpiSC-derived OPCs, we evaluated their myelinogenic potential by in vitro culture with neurons as well as by injection into the brains of congenitally hypomyelinated mice both in organotypic slice culture and in vivo. For in vitro culture studies, we plated EpiSC-derived p6 p7 p8 OPCs at low density onto cultures of mouse cortical neurons and allowed them to differentiate 2 . After 6 d, the EpiSC-derived OPCs had differentiated into MBP + cells. Much of the MBP + staining aligned with βIII-tubulin + axons, which is suggestive of their myelinogenic capacity (Fig. 3d) . EpiSC-derived OPCs previously exposed to T3 did not produce MBP + segments, which tracked with βIII-tubulin + cells, suggesting temporal restriction of myelinogenic potential. To assess the functionality of our EpiSC-derived OPCs, we developed a tractable organotypic slice culture assay to evaluate their myelinogenic potential. Injection of EpiSC-derived OPCs into coronal, forebrain slices of early postnatal shiverer (Mbp shi/shi ) pups (which lack Mbp and compact myelin) resulted in substantial numbers of Mbp + segments and compact myelin after 10 d ( Fig. 4a-c) .
Transplanted EpiSC-derived OPCs specifically differentiated into oligodendrocytes and did not form neurons in the shiverer brain slices (Supplementary Fig. 7a,b) . We also assessed the ability of EpiSC-derived OPCs to myelinate shiverer host axons in slice culture using both low-and high-passage-number cells with no differences evident (Fig. 4b) .
To assess the myelinogenic capacity of EpiSC-OPCs in vivo, we delivered 2.5 × 10 5 cells into the future corpus callosum of newborn, immunocompetent shiverer (Mbp shi/shi ) pups. We analyzed mouse brains 3-7 weeks after injection and assayed them for the presence of myelinated fibers in the brain. We found many patches of MBP + myelin sheaths in mice transplanted with EpiSC-derived OPCs but not in untransplanted controls (Fig. 4d) . Additionally, EpiSC-derived OPCs appeared to migrate extensively in the host central nervous system as we observed myelination at sites distant from the injection such as the contralateral striatum ( Fig. 4d) . We observed no teratomas or aberrant cellular growths in any of the mice transplanted with EpiSC-derived OPCs at the time points evaluated. Taken together, our results demonstrate that EpiSC-derived OPCs function to produce compact myelin and provide a tractable source of cells to optimize cell-based transplantation strategies for myelin repair.
A scalable screening platform for oPc differentiation
We next explored the ability of extrinsic factors to modulate the differentiation of EpiSC-derived OPCs. As this system allows for the scalable production of OPCs from pluripotent cells, it provides a platform to screen for molecules that influence the transition of OPCs into oligodendrocytes. This is especially pertinent to disorders such as multiple sclerosis where NG2 + OPCs are present in or close to demyelinated lesions but generally do not remyelinate demyelinated axons 26 . As a simple proofof-principle for using our system to screen for compounds, we exposed EpiSC-derived OPCs to three different treatment regimens involving modulation of signaling pathways (Notch, Wnt-β-catenin and BMP) previously implicated in oligodendrocyte development or differentiation. Treatment of EpiSC-derived OPCs for 2 d with T3 differentiation medium in the presence of the Notch ligand Jagged1 (Jag1) did not impact the rate or number of O4 + oligodendrocytes (Fig. 5a,b) . Using a similar protocol we tested the role of GSK3β, a negative regulator of Wnt-β-catenin signaling, by treating EpiSC-derived OPCs with the GSK3β inhibitor CHIR99021. This treatment resulted in a concentration-dependent inhibition of oligodendrocyte differentiation whereby cells remained Olig2 + OPCs and did not progress to O4 + oligodendrocytes (Fig. 5) . These results suggest that canonical Wnt-β-catenin signaling, activated by inhibition of GSK3β, may positively regulate the OPC state and block the transition to oligodendrocytes 27 . The final treatment involved exposure of EpiSC-derived OPCs to signaling cascades known to respecify OPCs in vitro into an alternate glial fate, astrocytes 28, 29 . Treatment of EpiSC-derived OPCs with BMP4 and leukemia inhibitory factor (LIF) resulted in the majority of cells undergoing morphological and gene expression changes including the upregulation of GFAP, indicative of respecification into astrocytes (Fig. 5d) . These results demonstrate that our scalable mouse pluripotent stem cell-based system provides a powerful way to screen for modulators of oligodendrocyte development and myelination.
discussion
Strategies to restore function in individuals afflicted with myelinbased disorders rely on either the modulation of endogenous OPCs or transplantation of exogenous myelinogenic cells. The ability to screen for relevant compounds or generate a homogenous population of transplantable cells requires a tractable system to generate sufficient quantities of functional OPCs for study. Thus far it has not been feasible to obtain the requisite number of OPCs in high purity regardless of the methodology used. Here we demonstrate a robust differentiation platform whereby mouse pluripotent stem cells are guided through a defined series of developmental transitions to recapitulate the complex signaling environments present in the developing embryo. Our approach allowed for the rapid production of pure, highly expandable populations of mouse OPCs, capable of differentiation into large numbers of functional oligodendrocytes with great efficiency. This developmental system will afford a detailed understanding of the gene expression changes and signaling pathway requirements throughout the entire oligodendrocyte lineage ( Supplementary Fig. 8 and Supplementary Table 1 ). These data may offer insight into the causative cell and molecular defects that function in congenital disorders impacting the oligodendrocyte lineage.
Our system is also a robust platform to perform high-throughput screens for drugs that modulate the functional differentiation of mouse OPCs. Our small-scale screen identified that inhibition of GSK3β, a negative regulator of the canonical Wnt-β-catenin signaling pathway, blocked the transition of mouse OPCs into functional oligodendrocytes. Previous work has also shown that the Wnt signaling pathway is aberrantly active in demyelinating lesions of human individuals with multiple sclerosis 27 . Together, these results suggest that our mouse EpiSC-based system may prove useful to screen for compounds that effectively target endogenous OPCs in individuals.
Remyelinating strategies may also require the provision of exogenous myelinogenic cells. Transplantation of fetal human glial progenitor cells has been shown to lead to recovery in a lethally hypomyelinated mouse model 30 . Although these previous studies established a proof of principle for translation to human individuals, cells from aborted human fetuses not only face ethical and immunological challenges but scalability to a large clinical quantity may not be realistic. Our results in the mouse show that pluripotent cells can be rapidly differentiated into OPCs capable of functional myelination. Future studies will take advantage of the purity and scalability of this system to optimize transplantation strategies (injection site, timing and dosing) for functional recovery from dysmyelinating conditions. As EpiSCs have defining features and differentiation responses in common with human embryonic stem cells and iPSCs, the potential extension of our OPC differentiation regimen to human pluripotent cells is an exciting prospect for the treatment of human myelin-related disorders in the future.
methods
Methods and any associated references are available in the online version of the paper at http://www.nature.com/naturemethods/.
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Note: Supplementary information is available on the Nature Methods website. online methods Differentiation of EpiSCs to neuroectoderm. All cells were cultured at 37 °C and 5% CO 2 unless otherwise noted. Individual EpiSC lines were isolated from mice of strains 129SvEv (EpiSC5 and EpiSC7 lines), (129O1 line) and 129SvEv x ICR (EpiSC9 line), and maintained in vitro as previously described in EpiSC base medium supplemented with 10 ng ml −1 FGF2 (R&D Systems, 233-FB) 8, 10, 31 . Differentiation of EpiSCs to patterned, neural rosettes was a 5-d procedure with complete medium changes every day.
EpiSC base medium consisted of Knockout DMEM (Invitrogen) supplemented with 20% Knockout Serum Replacement (KSR; Invitrogen), 2 mM Glutamax (Invitrogen), 1× nonessential amino acids (Invitrogen) and 0.1 mM 2-mercaptoethanol (Sigma).
Neural base medium consisted of DMEM/F12 (Invitrogen; 11320) supplemented with 1× N2 (R&D Systems), 1× B-27 without vitamin A (Invitrogen) and 2 mM Glutamax.
On day 0, EpiSCs were plated under standard passaging conditions in EpiSC base medium supplemented with 100 ng ml −1 noggin (R&D Systems), 20 µM SB431542 (Sigma; maintained as a 20 mM stock solution in DMSO) and 2 µM dorsomorphin (EMD; supplied as a 10 mM stock solution in DMSO). 0.1 µM LDN-193189 (Stemgent; maintained as a 1 mM stock solution according to the manufacturer's instructions) was used in place of dorsomorphin for some experiments. On day 1, cultures were fed with a 1:1 mixture of EpiSC base medium and neural base medium supplemented with 100 ng ml −1 noggin, 20 µM SB431542 and 2 µM dorsomorphin. On day 2, cultures were fed with neural base medium supplemented with 100 ng ml −1 noggin, 20 µM SB431542 and 2 µM dorsomorphin. On day 3, cultures were fed with neural base medium supplemented with 100 ng ml −1 noggin. On day 4, cultures were fed with neural base medium supplemented with 100 ng ml −1 noggin, 10 µM retinoic acid (Sigma; maintained as a 20 mM stock solution in DMSO) and 200 ng ml −1 SHH (R&D Systems; C24II).
Differentiation of EpiSC-derived patterned neuroectoderm to
OPCs. Day-5 patterned rosettes were released from the culture dish using 1.5 mg ml −1 collagenase IV (Invitrogen) and dissociated to a single cell suspension using TrypLE Select (Invitrogen). Cells were counted and plated at 4 × 10 4 cells cm −2 on Nunclon-∆ plates coated with 0.1 mg ml −1 poly(L-ornithine) (Sigma) followed by 10 µg ml −1 laminin (Sigma; L2020). Cells were grown in OPC medium consisting of neural base medium supplemented with 20 ng ml −1 FGF2, 20 ng ml −1 PDGF-AA (R&D Systems) and 200 ng ml −1 SHH, and fed every other day for 5 d. At this point cultures consisted of a highly pure population of proliferating OPCs.
OPC culture. Cultures of EpiSC-derived OPCs were maintained and expanded in neural base medium supplemented with 20 ng ml −1 FGF2, 20 ng ml −1 PDGF-AA and 200 ng ml −1 SHH or 20 ng ml −1 PDGF-AA, 200 ng ml −1 SHH, 100 ng ml −1 noggin, 10 µM dibutyryl cyclic-AMP sodium salt (Sigma), 100 ng ml −1 IGF-1 (R&D Systems) and 10 ng ml −1 NT3 (R&D Systems), and fed every other day. OPCs were grown on Nunclon-∆ plates coated with poly(L-ornithine) and laminin. Cells were passaged every 3-5 d with TrypLE Select and typically seeded at 2 × 10 4 cells cm −2 . OPCs could be readily frozen or thawed and were cryopreserved in DMEM supplemented with 10% FBS (Invitrogen) and 10% DMSO (Sigma).
For the cumulative OPC experiment (Fig. 2d) , at 'passage 0' we seeded 4 × 10 4 cells cm −2 . Subsequently, cells were passaged at 80-90% confluence and seeded at 2 × 10 4 cells cm −2 . Total cell number at each passage was counted with a hemocytometer. Rates of growth were determined at each passage and extended to the entire population of cells to yield a cumulative count.
Differentiation of EpiSC-derived OPCs. For differentiation of OPCs into oligodendrocytes, cells were plated at 2.2 × 10 4 cells cm −2 and induced with neural base medium supplemented with 0.4 ng ml −1 T3 (Sigma), 200 ng ml −1 SHH, 100 ng ml −1 noggin, 10 µM dibutyryl cyclic-AMP sodium salt, 100 ng ml −1 IGF-1 and 10 ng ml −1 NT3. Attempts to modulate the outcome of this differentiation paradigm included treatments with Jag1 (R&D Systems), CHIR99021 (Stemgent), LIF (Millipore) and/or BMP4 (R&D Systems). sequences). For PCR, Klentaq LA DNA polymerase (Clontech 639108) was used along with 1.3 M betaine. Cycling conditions for PCR were 93 °C for 1 min, 30 cycles of 93 °C for 20 s followed by 68 °C for 3 min, held at 4 °C.
Global gene expression. Cells were lysed in 1 ml TRIzol (Invitrogen) and stored at −80 °C until ready for use. Chloroform separation was enhanced with Phase-Lock Gel tubes (5 Prime). The aqueous phase was collected and the RNA isolation completed with the RNeasy Plus kit (Qiagen) according to the manufacturer's protocol. Biotinylated cRNA was prepared from 150 ng of total RNA using the Affymetrix GeneChip Whole Transcript Sense Target Labeling assay according to the manufacturer's instructions. Labeled cRNA (10 µg) was hybridized for 17 h at 45 °C on Affymetrix Mouse Gene 1.0 ST arrays, washed and stained in the Affymetrix Fluidics Station 450. Sample labeling and hybridization to Affymetrix Mouse Gene 1.0 ST arrays were carried out in the Gene Expression and Genotyping Core Facility of the Case Comprehensive Cancer Center. Cel files were generated with the Affymetrix GeneChip Command Console 2.0, and the data were normalized with the robust multiarray average (RMA) method using the default settings in Expression Console Software (Affymetrix). For clustering analysis in Supplementary Figure 8 , Shannon entropy was used to rank genes specific to each cell type 33 . Values for genes, where the Shannon entropy measure of tissue specificity (Q) was less than entropy (H) × 1.65, were Z-transformed 34 and samples were clustered with Gene Cluster 3.0 software using centroid linkage and displayed with Java Treeview software. This analysis generated 502, 491, 181 and 449 unique annotated genes specific to EpiSCs, day-5 neural rosettes, OPCs and oligodendrocytes, respectively (Supplementary Table 1) . The heatmap in Supplementary  Figure 3 was generated in R using the heatmap.2 function of the gplots package. For comparison of low-and high-passage-number OPCs and oligodendrocytes (passages 3 and 11) in Supplementary  Figure 6c , a correlation dendrogram was generated in R from Z-transformed whole-genome expression data (genes not expressed in any of the samples were excluded from analysis; total number of genes used was 13,183).
